USPTO Patent Application: Stable Liquid Bortezomib Formulations
Summary
The USPTO has published a patent application (US20260083760A1) for stable liquid bortezomib formulations filed by Riconpharma LLC. The application describes liquid compositions with specific impurity limits for intravenous or subcutaneous use.
What changed
This document is a USPTO patent application (US20260083760A1) for "STABLE LIQUID BORTEZOMIB FORMULATIONS" filed by Riconpharma LLC. The application details liquid compositions containing bortezomib, mannitol, and a pharmaceutically acceptable carrier, intended for intravenous or subcutaneous administration. Key aspects include strict limits on specific impurities (Impurity-E, L, J, F, I, U) not exceeding 1.0% individually, and total impurities not exceeding 3.0%.
As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future intellectual property and market exclusivity for Riconpharma LLC concerning these specific formulations. Companies involved in bortezomib development or manufacturing should be aware of this patent filing as it may impact their own research, development, and commercialization strategies in this therapeutic area.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
STABLE LIQUID BORTEZOMIB FORMULATIONS
Application US20260083760A1 Kind: A1 Mar 26, 2026
Assignee
Riconpharma LLC
Inventors
Mukteeshwar Gande, Praveen Reddy Billa, SVB Janardhan Garikipati, Vinay Sudhindra Raichur, Vijaya Kumar Thota
Abstract
Described herein are liquid compositions comprising: bortezomib; mannitol in an amount up to about 50 mg/mL; and a pharmaceutically acceptable carrier, wherein the liquid composition is for intravenous or subcutaneous use; and wherein the liquid composition comprises not more than (NMT) 1.0% of Impurity-E; Impurity-L; Impurity-J; Impurity-F; Impurity-I; or Impurity-U; and NMT than 3.0% of Total Impurities. Methods of making and using these compositions are also described herein.
CPC Classifications
A61K 31/69 A61K 9/0019 A61K 9/08 A61K 47/02 A61K 47/26
Filing Date
2025-09-26
Application No.
19341758
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.